Arend, R. C., Monk, B. J., Shapira-Frommer, R., Secord, A. A., Herzog, T. J., Tewari, K. S., … Penson, R. T. (2023). Randomized controlled phase III trial of weekly paclitaxel ± ofranergene obadenovec (VB-111) for platinum-resistant ovarian cancer (OVAL Study/GOG 3018). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).

Arend, Rebecca Christian, Bradley J. Monk, Ronnie Shapira-Frommer, Angeles Alvarez Secord, Thomas J. Herzog, Krishnansu Sujata Tewari, Jonathan A. Ledermann, et al. “Randomized controlled phase III trial of weekly paclitaxel ± ofranergene obadenovec (VB-111) for platinum-resistant ovarian cancer (OVAL Study/GOG 3018).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.

Arend RC, Monk BJ, Shapira-Frommer R, Secord AA, Herzog TJ, Tewari KS, et al. Randomized controlled phase III trial of weekly paclitaxel ± ofranergene obadenovec (VB-111) for platinum-resistant ovarian cancer (OVAL Study/GOG 3018). In: JOURNAL OF CLINICAL ONCOLOGY. 2023.

Arend, Rebecca Christian, et al. “Randomized controlled phase III trial of weekly paclitaxel ± ofranergene obadenovec (VB-111) for platinum-resistant ovarian cancer (OVAL Study/GOG 3018).” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 16, 2023.

Arend RC, Monk BJ, Shapira-Frommer R, Secord AA, Herzog TJ, Tewari KS, Ledermann JA, Minei TR, Buyse ME, Haggerty A, Alvarez EA, Amit A, Muller C, Herraez AC, Holman LL, Cohen J, Huang M, Yachnin A, Harats D, Penson RT. Randomized controlled phase III trial of weekly paclitaxel ± ofranergene obadenovec (VB-111) for platinum-resistant ovarian cancer (OVAL Study/GOG 3018). JOURNAL OF CLINICAL ONCOLOGY. 2023.